Table 3.
Methodologies and outcomes of clinical trials of erenumab in episodic migraine.
| ARISE90 | STRIVE91 | LIBERTY92 | |
|---|---|---|---|
| Number of participants | 577 | 955 | 246 |
| Erenumab dose | 70 mg | 70 mg and 140 mg | 140 mg |
| Number of preventive treatments failed | <3 treatments | <3 treatments | 2–4 treatments |
| Trial duration | 12 weeks | 24 weeks | 12 weeks |
| Change in mean MMD | –2.9 days | –3.2 days (70 mg) –3.7 days (140 mg) |
–1.8 days |
| Therapeutic gain | –1.1 days | –1.4 days (70 mg) –1.9 days (140 mg) |
–1.6 days |
| Change in acute medication days/month | –1.2 | –1.1 (70 mg) –1.6 (140 mg) |
–1.3 |
| Rate of 50% responders | 39.7% | 43.3.% (70 mg) 50.0% (140 mg) |
30% |
| HIT-6 | –4.9 (gain: –2.3) | Not used | Not used |
| Discontinuation rate due to side effects | 1.8% | 2.2% (70 mg) 2.2% (140 mg) |
0% |
MMD, monthly migraine days.